Australian experts note about half a million people there use GLP-1 drugs for diabetes alone, and lay out what new users should keep in mind about nutrition.
Recap by typeshit. Full story at Medical Xpress.
The REDEFINE 1 data covered 2,309 women, with placebo at 3%. In the REDEFINE 4 head-to-head, tirzepatide matched or slightly beat it.
Superpower says the drug carries radiation straight to cancer cells and cites a phase 3 trial showing a 79% lower risk of progression or death. A 14-part thread.
A herpetology-themed clip from PBS points to reptiles as part of the story behind today's GLP-1 medications. Short and light, but a fun bit of history.
Novo says results held across menopausal stages among 1,900 women, from 23.1% to 26.7%, against about 2% on placebo. The piece also pitches obesity ETFs.
An opinion piece drawing on Sabrina Strings to tie GLP-1 culture, celebrity ads and Ozempic-friendly menus to class and belonging.
8:58
Constable, who bills herself as a peptide expert, lists side effects she links to the unapproved triple agonist. Her claims, not trial data, so weigh them accordingly.
Loading…